All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
On 27th April 2017, in an article published ahead of print in Acta Haematologica, Hongyu Zhao and colleagues from the Jinan Central Hospital, Jinan, China, discuss results from their retrospective single-center study.
Zhao et al. retrospectively studied the safety and efficacy of decitabine given prior to full-dose idarubicin and cytarabine (D-IA) in patients with Refractory or Recurrent (R/R) Acute Myeloid Leukemia (AML).
In total, twenty-one R/R AML patients (median age = 43) treated between 2013–2016 at the Jinan Central Hospital were included in this study. Patients received either one cycle of the D-IA regimen (20 mg/m2 decitabine on days 1–5, 10 mg/m2 idarubicin on days 6–8, and 100 mg/m2 cytarabine on days 6–10) or additional cycles depending on if they achieved Complete Response (CR) or if bone marrow blasts decreases by > 50%.
The authors concluded their study by stating that the D-IA regimen “was well tolerated” and the ORR was “encouraging”. They further suggested that the D-IA regimen “may offer a novel and potentially effective” therapeutic strategy for R/R AML patients.
To investigate the safety and efficacy of the triple therapy of decitabine, idarubicin, and cytarabine in the treatment of refractory or recurrent acute myeloid leukemia (R/R AML).
We conducted a single-center retrospective study in which decitabine treatment was administered prior to full-dose idarubicin and cytarabine (D-IA) for 21 R/R AML patients.
After 1 cycle of D-IA, 10/21 (47.6%) patients experienced a complete remission (CR) and 2/21 (9.5%) showed a partial response. There was a 1-month response rate (RR) in 12/21 patients (57.14%); these patients achieved CR after 2 cycles of D-IA. Five of these 12 (40%) patients then received sequential allogeneic stem cell transplantation. At the last follow-up date, 9/21 (42.8%) patients had survived, and 7/21 (33.3%) were in continuous CR. Hematological toxicity and infections were the most prominent toxicities of this regimen. Other toxicities included nausea, vomiting, bleeding, and liver enzyme abnormalities. No mortalities were recorded due to treatment-related toxicity during remission.
The combination was well tolerated, and the RR was encouraging. Our study suggests that D-IA may offer a novel and potentially effective treatment regimen for R/R AML patients.